A new FLT3 inhibitor with two cases: the gilteritinib experience

Basit Öğe Kaydı
dc.authoridMehmet Hilmi Doğu / 0000-0001-7237-2637
dc.authorscopusidMehmet Hilmi Doğu / 55212747300
dc.authorwosidMehmet Hilmi Doğu / W-2255-2017
dc.contributor.authorSerin, Istemi
dc.contributor.authorDoğu, Mehmet Hilmi
dc.contributor.authorHuq, Gulben Erdem
dc.contributor.authorYokus, Osman
dc.date.accessioned2021-07-28T07:05:21Z
dc.date.available2021-07-28T07:05:21Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractIntroduction: In acute myeloid leukemia (AML), a heterogeneous group of leukemias, there are various factors to determine prognosis. Among these prognostic factors, cytogenetic results are increasing in importance day by day. FLT3 mutations are among the most common molecular abnormalities in AML, patients with recurrent or refractory (R/R) AML with this mutation have a low response rate to salvage therapy. Gilteritinib has activity against FLT3, ALK and AXL. This article shall present two cases, for which Gilteritinib was used, a new FLT3 inhibitor, and the results of the treatment. Case 1: A 52-year-old female patient presented to the emergency clinic with weakness and fever. In initial biochemical analysis, leukocyte was 104000/mm(3). Peripheral smear contained diffuse myeloid blastoid cells, peripheral blood flow cytometry also supported the AML M0-1 phenotype. The bone marrow biopsy aspiration performed on the 14th day of induction "3+7" treatment, contained diffuse blastic infiltrate and supported refractory disease. In addition to the FLAG-IDA salvage regimen, 120 mg/day Gilteritinib was also started. Bone marrow aspiration performed on the 28th day of salvage therapy was compatible with remission. Case 2: 53 years old male patient with also no comorbidity other than known hypertension. In the initial biochemical analysis of the patient, leukocyte was 156000/mm(3), platelet 58000/mm(3) and hemoglobin 7.6 g/dl. Peripheral blood flow cytometry supported the AML M5 phenotype, whose peripheral smear showed diffuse monoblastoid cells. On the 14th day of the patient's 3+7 induction treatment, the control bone marrow aspiration showed diffuse blast infiltration and was considered refractory, FLAG-IDA salvage therapy with again 120 mg/day Gilteritinib per oral were started. On the 28th day, control bone marrow aspiration was evaluated as remission. Discussion and conclusion: Unlike other FLT 3 inhibitors, Gilteritinib has been shown to be a highly effective agent in R/R AML with FLT3 mutations. Being the first data to be reported from Turkey, we think it would be quite guiding the titular.en_US
dc.identifier.citationSerin, I., Dogu, M. H., Huq, G.E., & Yokus, O. (2021). A new FLT3 inhibitor with two cases: the gilteritinib experience. AMERICAN JOURNAL OF BLOOD RESEARCH 11(3), 271-278.en_US
dc.identifier.endpage278en_US
dc.identifier.issn2160-1992en_US
dc.identifier.issue3en_US
dc.identifier.pmid34322291en_US
dc.identifier.startpage271en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1950
dc.identifier.volume11en_US
dc.identifier.wosWOS:000672609100009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorDoğu, Mehmet Hilmi
dc.language.isoenen_US
dc.publisherE-CENTURY PUBLISHING CORPen_US
dc.relation.ispartofAMERICAN JOURNAL OF BLOOD RESEARCHen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcute Myeloid Leukemiaen_US
dc.subjectRefractoryen_US
dc.subjectFLT3en_US
dc.subjectGilteritiniben_US
dc.subjectPrognosisen_US
dc.titleA new FLT3 inhibitor with two cases: the gilteritinib experienceen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
109.pdf
Boyut:
968.39 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu